Take a fast-food loving culture, mix in a sedentary lifestyle, and, not surprisingly, you get a lot of heart disease in the U.S. The trend doesn’t appear to be changing anytime soon, as the Baby Boomers get older, and an estimated 18 million U.S. adults are living with some form of cardiovascular disease. So if … Continue reading “Four Big Cardiovascular Trends to Watch at this Week’s Medical Device Gathering—TCT 2010”
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
Buteeq Raises $1.1M
Seattle-based Buteeq, a stealthy developer of mobile phone applications, has raised $1.1 million in new equity financing, according to a report in TechFlash. Adam Brownstein, a veteran of Microsoft and Sony, heads up the company, according to TechFlash.
Lycera CEO Resigns After Less Than One Year, Michigan Startup Plans to Keep Boston Presence
The CEO of Lycera, one of Michigan’s high-profile biotech startups, has left the company after less than a year on the job. CEO Bill Sibold, the former Biogen Idec executive who was hired to lead the Plymouth, MI-based startup in January, has resigned to pursue other interests, Xconomy has confirmed. Sibold’s corporate biography no longer … Continue reading “Lycera CEO Resigns After Less Than One Year, Michigan Startup Plans to Keep Boston Presence”
Nodality’s Personalized Medicine Recipe, Relypsa Pockets $70M, Big Oil Likes Seaweed Biofuel, & More Bay Area Life Sciences News
One of the best things about covering life sciences innovation is weeks like this when we get to write about topics as diverse as seaweed biofuel and personalized cancer treatment. Get caught up on the week’s biotech headlines here. —One fascinating new take on personalized cancer treatment is emerging in South San Francisco at Nodality, … Continue reading “Nodality’s Personalized Medicine Recipe, Relypsa Pockets $70M, Big Oil Likes Seaweed Biofuel, & More Bay Area Life Sciences News”
Cell Therapeutics Finds Way to Survive, Persuading Investors to OK Sale of 400M Shares
[Updated: 6:20 pm Pacific] Cell Therapeutics isn’t ready to close its doors just yet, even after suffering what could have been a fatal setback this year. The Seattle-based biotech company (NASDAQ: [[ticker:CTIC]]), which had a new drug application soundly rejected by the FDA in April, said today that shareholders have given it the green light … Continue reading “Cell Therapeutics Finds Way to Survive, Persuading Investors to OK Sale of 400M Shares”
Alkermes Wins FDA Panel Nod
Alkermes (NASDAQ: [[ticker:ALKS]]), the Waltham, MA-based biotech company, received some good news today from an FDA advisory panel. The FDA’s panel of psychiatric drug experts voted 12-1 to recommend that the FDA approve Alkermes’ long-lasting naltrexone (Vivitrol) as a treatment for opioid dependence. The FDA, which usually follows the recommendations of its advisory panels, has … Continue reading “Alkermes Wins FDA Panel Nod”
Arena Pharmaceuticals Obesity Drug Shot Down by FDA Panel
San Diego-based Arena Pharmaceuticals (NASDAQ: [[ticker:ARNA]]) and its partner, Japan-based Eisai Pharmaceuticals, suffered a big-time setback today in their quest to bring a new obesity drug to the U.S. market. The FDA’s expert advisory panel on endocrinology and metabolic drugs said today in a 9-5 vote that lorcaserin (Lorqess) shouldn’t be approved for sale in … Continue reading “Arena Pharmaceuticals Obesity Drug Shot Down by FDA Panel”
Infinia, InnovaTek Win U.S. Grants
Two companies from the Tri-Cities, Kennewick, WA-based Infinia and Richland, WA-based InnovaTek, have received commercialization grants from the U.S. Department of Energy. Infinia, the developer of solar power generators, is getting $1.5 million for what the Department of Energy calls a “high-efficiency maintenance-free cryocooler” for high-temperature superconductors. InnovaTek will receive $2.2 million to generate power … Continue reading “Infinia, InnovaTek Win U.S. Grants”
Nodality Nears Market With Technology to Get the Right Cancer Drug to the Right Patients
One fascinating new idea in predictive, personalized medicine is starting to gather momentum in South San Francisco. Nodality, a Stanford University spinoff from the lab of biologist Garry Nolan, is now on the cusp of going commercial with technology to help Big Pharma companies, and doctors, better understand why individuals respond differently to drugs, and … Continue reading “Nodality Nears Market With Technology to Get the Right Cancer Drug to the Right Patients”
NanoBio Passes First Key Clinical Trial With Nasal Flu Vaccine, Scopes Other Opportunities
NanoBio has its sights set on developing a new generation of vaccines against the flu and other pathogens, and this past week the Ann Arbor, MI-based company showed the first real evidence in human beings that its approach might work. An initial study of 199 healthy adults, presented over the weekend at the Interscience Conference … Continue reading “NanoBio Passes First Key Clinical Trial With Nasal Flu Vaccine, Scopes Other Opportunities”
Seattle Genetics’ Dark Horse Fails, The Future of Zymo’s Landmark, PATH Nabs Flu Vaccine Contract, & More Seattle-Area Life Sciences
Seattle biotech is still buzzing more than a week later about Bristol-Myers Squibb’s acquisition of ZymoGenetics (NASDAQ: [[ticker:ZGEN]]) and whether it means we live in some dead-end biotech loserville. If you have some thoughts on this, please shoot me a note, because the last words haven’t yet been written on the Zymo deal. —Everyone wants … Continue reading “Seattle Genetics’ Dark Horse Fails, The Future of Zymo’s Landmark, PATH Nabs Flu Vaccine Contract, & More Seattle-Area Life Sciences”
Fierce 15 Shines Light on Some of Our Favorite Companies in Boston and Beyond
I’ve never actually met the folks at FierceBiotech in person, but today I felt like we had undergone some kind of Vulcan mind meld. The online industry publication unveiled its annual Fierce 15 list of the 15 most promising private biotech companies in the U.S. What jumped out at me right away? All but one … Continue reading “Fierce 15 Shines Light on Some of Our Favorite Companies in Boston and Beyond”
Alder Wins Fierce 15 Honor
Alder Biopharmaceuticals, the Bothell, WA-based maker of antibody drugs, was honored today as one of the nation’s 15 most promising biotech companies, in the annual Fierce 15 list published by FierceBiotech. Alder emerged from the ashes of Celltech R&D back in 2003 to secure a billion-dollar partnership last year from Bristol-Myers Squibb to develop a … Continue reading “Alder Wins Fierce 15 Honor”
Seaweed Biofuel Maker, Bio Architecture Lab, Snags Partnership With Norway’s Statoil
A startup with a dream of turning seaweed into renewable biofuels just got some important validation from a big oil company. Berkeley, CA-based Bio Architecture Lab said today it has secured a partnership with the world’s biggest offshore oil and gas producer, Norway-based Statoil, to build up capabilities to turn seaweed from off the Norwegian … Continue reading “Seaweed Biofuel Maker, Bio Architecture Lab, Snags Partnership With Norway’s Statoil”
Bluebird Bio, Third Rock & Genzyme’s Gene Therapy Bet, Shows Promise for Blood Disorder
Genzyme and Third Rock Ventures bet $35 million six months ago on a Cambridge, MA-based gene therapy company. Despite all the ups and downs with gene therapy over the years, now we can see why they placed the bet. The newly renamed Bluebird Bio, formerly known as Genetix Pharmaceuticals, is coming out today with an … Continue reading “Bluebird Bio, Third Rock & Genzyme’s Gene Therapy Bet, Shows Promise for Blood Disorder”
Tetraphase Shows What the $45M Was All About at Big Antibiotics Conference
Tetraphase Pharmaceuticals raised a big $45 million venture round back in June, and now scientists can see more clearly why it’s been able to raise all that dough. The Watertown, MA-based company made a series of 10 different poster presentations over the past few days at the biggest antibiotics meeting of the year, the Interscience … Continue reading “Tetraphase Shows What the $45M Was All About at Big Antibiotics Conference”
PATH Snaps Up $5M Contract to Make Flu Vaccines For Stockpiling, Hot Conditions
One of the big ideas PATH is pursuing to make vaccines more useful just got a strong vote of confidence. The Seattle-based global health nonprofit is announcing today it has secured a $5.2 million contract from the U.S. government to develop flu vaccines that can remain effective for years when they are stashed away in … Continue reading “PATH Snaps Up $5M Contract to Make Flu Vaccines For Stockpiling, Hot Conditions”
Genentech CEO Leaves Dendreon Board
Seattle-based Dendreon (NASDAQ: [[ticker:DNDN]]) said today that Ian Clark, the CEO of Roche’s U.S.-based Genentech unit, is resigning from the Dendreon board. Clark was named to the Dendreon board just 11 months ago, along with former Eli Lilly executive Pedro Granadillo, as part of the company’s effort to add more board expertise in sales, marketing, … Continue reading “Genentech CEO Leaves Dendreon Board”
Seattle Genetics Snags Genmab Deal
Seattle Genetics, the developer of targeted antibody drugs, said today it has provided a license to Denmark-based Genmab to develop “empowered antibodies” against a target called Tissue Factor antigen found on numerous solid tumors. Seattle Genetics (NASDAQ: [[ticker:SGEN]]) is getting an undisclosed upfront fee, and retains an option to co-develop any drugs it wants on … Continue reading “Seattle Genetics Snags Genmab Deal”
Arena Obesity Drug Was Effective by ‘Slim Margin,’ FDA Staff Raises Rat Cancer Concern; Shares Tumble
Arena Pharmaceuticals (NASDAQ: [[ticker:ARNA]]) has spent a dozen years working on developing a new drug with potential to help millions of people lose weight. Now U.S. regulators have had a chance to comb through detailed clinical trial results, and found it passed one of the two common standards for effectiveness of an obesity drug by … Continue reading “Arena Obesity Drug Was Effective by ‘Slim Margin,’ FDA Staff Raises Rat Cancer Concern; Shares Tumble”
Ironwood Pharma Passes Third Big Clinical Trial With Constipation Drug, Shares Climb
Ironwood Pharmaceuticals went public earlier this year after passing its first two pivotal clinical trials. Now the company has cleared its third major clinical hurdle, which sent the Cambridge, MA-based company’s shares (NASDAQ:[[ticker:IRWD]]) up by more than 15 percent in after-hours trading. Ironwood’s experimental drug reached its goal of relieving abdominal pain/discomfort and helping reduce … Continue reading “Ironwood Pharma Passes Third Big Clinical Trial With Constipation Drug, Shares Climb”
Santarus Adds Two Drugs
Santarus, the San Diego-based drug developer, said today it has acquired two biotech drugs. Santarus (NASDAQ: [[ticker:SNTS]]) said it has acquired recombinant human C1 inhibitor (Rhucin) for hereditary angioedema from Netherlands-based Pharming Group for a $15 million upfront free and a $5 million milestone payment. Santarus is also getting a humanized anti-VLA1 antibody drug for … Continue reading “Santarus Adds Two Drugs”
Relypsa Snags $70M Venture Round to Get Rid of Excess Potassium in Blood
The people who made a bundle off a company called Ilypsa may just have found a hit in their second act. Santa Clara, CA-based Relypsa said today it has nailed down $70 million in a Series B round of venture financing to pursue a new drug that tamps down excessive potassium in the blood. OrbiMed … Continue reading “Relypsa Snags $70M Venture Round to Get Rid of Excess Potassium in Blood”
What Will Happen to ZymoGenetics’ Landmark Headquarters when Bristol Calls the Shots?
The big question these days in Seattle biotech is about people. What will happen to the 320 people who work at ZymoGenetics (NASDAQ: [[ticker:ZGEN]]), now that the pioneering company has agreed to be taken over by pharmaceutical giant Bristol-Myers Squibb for $885 million? Given the history of takeovers like this, the safe bet is that … Continue reading “What Will Happen to ZymoGenetics’ Landmark Headquarters when Bristol Calls the Shots?”
Seattle Genetics’ Dark Horse Drug Candidate Fails in Key Study
Seattle Genetics has struck out in its bid to treat one of the more aggressive forms of leukemia. The Bothell, WA-based biotech company (NASDAQ: [[ticker:SGEN]]) is announcing today that one of its experimental antibody drugs failed to help people with acute myeloid leukemia live longer in a clinical trial. The study of 210 patients, which … Continue reading “Seattle Genetics’ Dark Horse Drug Candidate Fails in Key Study”
Have a Beer With Carl Weissman and Me Monday at Xconomy Meetup
We spend a lot of time breaking stories and thinking about big events here at Xconomy, but sometimes we like to kick back at a local watering hole to just chat informally with readers. So we’re carving out time to do this, starting Monday, for the first of what we expect will be a series … Continue reading “Have a Beer With Carl Weissman and Me Monday at Xconomy Meetup”
Genzyme Cutting 1,000 Jobs Over Next 15 Months
Cambridge, MA-based Genzyme (NASDAQ: [[ticker:GENZ]]) is cutting 1,000 jobs over the next 15 months, as it faces intense pressure from shareholders to recover from manufacturing woes and deal with a takeover bid from Paris-based drug giant Sanofi-Aventis. Genzyme CEO Henri Termeer described the job cut plan this morning in a memo to employees. The layoffs … Continue reading “Genzyme Cutting 1,000 Jobs Over Next 15 Months”
iPierian Entices Corporate VCs, Plexxikon’s One-Two Punch, Jennerex’s Road Less Traveled, & More Bay Area Life Sciences News
We had news from the world of cancer drugs, genomics, stem cells, and an interesting little piece on a strategy for potentially preventing chronic fatigue syndrome. Get caught up here. —Emeryville, CA-based Onyx Pharmaceuticals (NASDAQ: [[ticker:ONXX]]) said it has struck a partnership with Japan-based Ono Pharmaceuticals. The deal provides about $59 million in upfront cash … Continue reading “iPierian Entices Corporate VCs, Plexxikon’s One-Two Punch, Jennerex’s Road Less Traveled, & More Bay Area Life Sciences News”
Who Will Pay For Innovation in the 21st Century? Find Out at Xconomy “VC Crossfire” Oct. 28
Some say the days when venture capitalists could bet big on risky, world-changing companies like Google and Genentech are in the past. The prolonged sluggish period in the U.S. economy has taken a toll, and an estimated one-third to one-half of all venture funds are thought to be slowly going out of business. Many VC … Continue reading “Who Will Pay For Innovation in the 21st Century? Find Out at Xconomy “VC Crossfire” Oct. 28″
Acceleron Snags $498M Deal With Shire to Develop Muscular Dystrophy Drugs
Shire has got to be feeling a little extra bounce in its step, as one of its competitors (Genzyme) has wobbled recently, and today it’s continuing its bold push forward in the world of rare diseases in a big partnership with Cambridge, MA-based Acceleron Pharma. Shire (NASDAQ: [[ticker:SHGPY]]), the U.K-based company that’s become an increasingly … Continue reading “Acceleron Snags $498M Deal With Shire to Develop Muscular Dystrophy Drugs”
Jennerex, Charging Ahead With Tumor-Killing Virus, Follows Biotech Road Less Traveled
Sometimes the innovation community can be a tough insider’s club. If you’re a biotech startup, you’re only real when Merck/Pfizer/Novartis/Glaxo/Roche or some big VC like Kleiner Perkins bets cash that says you might be real. So sometimes a potentially groundbreaking idea has to find some other way to get critical support. That’s what San Francisco-based … Continue reading “Jennerex, Charging Ahead With Tumor-Killing Virus, Follows Biotech Road Less Traveled”
ZymoGenetics Reaches the End, Stratos Genomics Nabs $4M, Children’s New Ventilator, & More Seattle-Area Life Sciences News
One huge story hit Seattle biotech this week. I got all the usual “who, what, when, where” in the initial reports. But I’m still thinking hard about the nuances of why this happened, and what will come next. Stay tuned. —The big news, of course, came when Bristol-Myers Squibb said it has agreed to acquire … Continue reading “ZymoGenetics Reaches the End, Stratos Genomics Nabs $4M, Children’s New Ventilator, & More Seattle-Area Life Sciences News”
Helicos Files Suit Against PacBio
Cambridge, MA-based Helicos Biosciences (NASDAQ: [[ticker:HLCS]]), the maker of gene sequencing instruments, said today it has filed a lawsuit accusing Menlo Park, CA-based Pacific Biosciences of patent infringement. Helicos says it was the first to invent and market the technology known as single molecule sequencing, and that PacBio’s subsequent technology violates Helicos patents that extend … Continue reading “Helicos Files Suit Against PacBio”
Swedish Names Chief Scientist
Seattle-based Swedish Medical Center said today that it named Dr. Mark Reisman, a well-known interventional cardiologist, to the new position of chief scientific officer and head of research. Reisman is taking on the new role as part of an expanded research program at Swedish, which the hospital says is intended to advance research, but also … Continue reading “Swedish Names Chief Scientist”
iPierian Nabs $28M, With New Backing From Glaxo and Biogen Idec, To Use Stem Cells for Drug Discovery
One of the Bay Area’s promising stem cell startups just got a big shot of cash from a couple of major pharmaceutical players in Boston. South San Francisco-based iPierian is announcing today it has secured a full $28 million in its Series B venture round, which includes GlaxoSmithKline’s SR One venture arm, along with Biogen … Continue reading “iPierian Nabs $28M, With New Backing From Glaxo and Biogen Idec, To Use Stem Cells for Drug Discovery”
Onyx Pockets $59M Upfront From Japanese Partner, to Market Myeloma Drugs
Onyx Pharmaceuticals has found a new partner to help sell its lead drug candidate for multiple myeloma in Japan, less than two months after it unveiled some promising clinical trial results. The Emeryville, CA-based developer of cancer drugs (NASDAQ: [[ticker:ONXX]]) is announcing today that it has struck a new partnership with Japan-based Ono Pharmaceutical, in … Continue reading “Onyx Pockets $59M Upfront From Japanese Partner, to Market Myeloma Drugs”
Jennerex Snags $116M Deal With Transgene
Jennerex, a San Francisco-based developer of cancer treatments, is announcing today it has struck a deal with France-based Transgene. Under the deal, Transgene has made an undisclosed equity investment, agreed to pay milestone payments worth as much as $116 million, and provide Jennerex with a double digit percentage royalty on sales of JX-594. In return, … Continue reading “Jennerex Snags $116M Deal With Transgene”
ZymoGenetics Reaches End of Road in Seattle, Faces Uncertain Future, Potential Job Cuts
[Updated: 5:12 pm Pacific, 9/7/10] ZymoGenetics, the company that once aspired to replace Immunex as the anchor company of Seattle’s biotech cluster, has reached the end of its road as an independent company. Many of its 320 employees could potentially lose their jobs as part of a takeover agreement reached with Bristol-Myers Squibb. The companies … Continue reading “ZymoGenetics Reaches End of Road in Seattle, Faces Uncertain Future, Potential Job Cuts”
ZymoGenetics, Seattle Biotech Pioneer, Acquired by Bristol-Myers for $885M
Big breaking news just hit the Seattle biotech community. Seattle-based ZymoGenetics, a pioneer in the Northwest life sciences cluster that was founded back in 1981, has agreed to be acquired by pharmaceutical giant Bristol-Myers Squibb for $885 million. The deal, approved by the boards of both companies, values ZymoGenetics (NASDAQ: [[ticker:ZGEN]]) at $9.75 per share—a … Continue reading “ZymoGenetics, Seattle Biotech Pioneer, Acquired by Bristol-Myers for $885M”
Vertex Nails Third Big Trial With Hepatitis C Drug, In Toughest Patients to Treat
Vertex Pharmaceuticals stepped up to the plate this year with three big swings for the fence, and it can now say it has gone 3-for-3. The Cambridge, MA-based biotech company (NASDAQ: [[ticker:VRTX]]), which has significant operations in San Diego, is announcing today that a combination of standard treatment and its novel drug for hepatitis C … Continue reading “Vertex Nails Third Big Trial With Hepatitis C Drug, In Toughest Patients to Treat”
Stratos Genomics Raises $4M, Pushes Ahead in Competitive Field of Low-Cost DNA Sequencing
Stratos Genomics, a Seattle-based developer of low-cost gene sequencing technology, said today it has raised $4 million in a Series A round of venture financing. The deal was led by Fisk Ventures, and included Stratos Group LLC. While the amount of investment isn’t huge, the fact that Stratos raised the cash is interesting on its … Continue reading “Stratos Genomics Raises $4M, Pushes Ahead in Competitive Field of Low-Cost DNA Sequencing”
Insilicos Gets $1.2M NIH Grant
Insilicos, a Seattle-based developer of biomedical software and diagnostics, has secured a $1.2 million grant from the National Institutes of Health, through the Small Business Innovation Research program, to study a potential new test for people with chest pain. The test will be given to 400 patients at the University of Washington with cardiovascular disease, … Continue reading “Insilicos Gets $1.2M NIH Grant”
Plexxikon Shows How New Drug Hits Molecular Target for Deadly Skin Cancer
Plexxikon has just landed a one-two punch in a couple of the world’s top medical and scientific journals. Just a couple weeks after the Berkeley, CA-based biotech company delivered some eye-opening results in the New England Journal of Medicine on its drug candidate for a deadly type of skin cancer, it is following that up … Continue reading “Plexxikon Shows How New Drug Hits Molecular Target for Deadly Skin Cancer”
Cerus, With Technology to Knock Out Viruses in Blood, Finds New Potential in Chronic Fatigue
Cerus has struggled for years to convince regulators that its technology for ridding the nation’s blood supply of pathogens deserves a chance on the U.S. market. Now the Concord, CA-based biotech company is pinning some renewed hope for its business on a study that says it can wipe out a newly discovered virus that some … Continue reading “Cerus, With Technology to Knock Out Viruses in Blood, Finds New Potential in Chronic Fatigue”
Emerald BioStructures Forms Deal
Emerald BioStructures, the contract research firm in Bainbridge Island, WA, said today it has formed a new collaboration with Boulder, CO-based SomaLogic. The deal calls for Emerald to provide its expertise in determining precise crystal structures of protein targets on cells, so that SomaLogic can make specific “aptamer” drugs, and small molecules, that bind tightly … Continue reading “Emerald BioStructures Forms Deal”
Orexigen Nabs $1B Deal With Takeda to Market Obesity Drug, Shares Climb
San Diego-based Orexigen Therapeutics has found a partner to help it compete in the growing market for drugs to combat obesity. It’s Japan-based Takeda Pharmaceutical. Under the terms of the deal, Takeda has obtained an exclusive license from Orexigen to market the combination drug of bupropion/naltrexone (Contrave) in the U.S., Canada, and Mexico. In return, … Continue reading “Orexigen Nabs $1B Deal With Takeda to Market Obesity Drug, Shares Climb”
Seattle Children’s CEO, Between Meetings, Invents Cheap Ventilator to Save Babies Worldwide
Being a hospital CEO sounds like a mind-numbing, innovation-crushing job to me. I imagine days filled with insurance hassles, egotistical docs, malpractice lawyers, and boring meetings about saving on rubber gloves. At night, I envision wining and dining donors to keep the place afloat. But in between doing everything that a hospital CEO must do, … Continue reading “Seattle Children’s CEO, Between Meetings, Invents Cheap Ventilator to Save Babies Worldwide”
What Is Boston Doing for the War on Cancer? Find Out at Xconomy Forum on October 20
Billions of dollars are being poured into R&D against cancer, by governments and pharma companies all over the world. I write about it pretty much every week on Xconomy. So it shouldn’t be any surprise we’ve been itching around here to pull off a socko event that gathers some of Boston’s top entrepreneurs in the … Continue reading “What Is Boston Doing for the War on Cancer? Find Out at Xconomy Forum on October 20”
Five Prime Therapeutics, Gliding Like a Submarine, Quietly Takes Aim At Cancer
Five Prime Therapeutics is one of those companies built on the old school biotech business model. Take a cutting-edge scientific concept, mix in top scientists and big name venture backers, and see what you get 10 years later. Now it’s been eight years, and the company is moving toward the point in clinical trials where … Continue reading “Five Prime Therapeutics, Gliding Like a Submarine, Quietly Takes Aim At Cancer”
Anchor Therapeutics Nabs $10M for New Class of Peptide Drugs Against Hard Targets
One of the many companies in Boston taking a shot at developing a new class of therapies has gotten a second vote of confidence from investors. Cambridge, MA-based Anchor Therapeutics has secured a $10 million Series B round of financing from its current investors, TVM Capital, HealthCare Ventures, and the Novartis Option Fund. Anchor, formerly … Continue reading “Anchor Therapeutics Nabs $10M for New Class of Peptide Drugs Against Hard Targets”